Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI …

Postmenopausal osteoporosis: Greater than 5% and more common than placebo: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, …
Source: back pain